Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | September 2008 |
| End Date: | August 2019 |
The purpose of this study is to identify tumor cells in the bloodstream (Circulating Tumor
Cells, CTC's) from patient's with locally advanced or metastatic (stage IV) breast cancer.
Analyzing the tumor is helpful in guiding therapy; however, research has suggested that the
number of tumor cells found in the bloodstream (CTC's) signifies more aggressive behavior and
increased difficulty in eliminating the cancer. This research will help to develop better
ways to treat breast cancer which could be tailored to a patient and may be adjusted to a
patient's individual needs.
Cells, CTC's) from patient's with locally advanced or metastatic (stage IV) breast cancer.
Analyzing the tumor is helpful in guiding therapy; however, research has suggested that the
number of tumor cells found in the bloodstream (CTC's) signifies more aggressive behavior and
increased difficulty in eliminating the cancer. This research will help to develop better
ways to treat breast cancer which could be tailored to a patient and may be adjusted to a
patient's individual needs.
Up to 60 mL of blood will be collected from each patient at up to 6 time points. Samples will
be delivered to the Bruce Laboratory (Palo Alto Research Center) for immunolabeling and FAST
scanning. The FAST scanning will utilize CK+, CD45-and DAPI+ labeling as well as cell
morphology confirmed by collaborating pathologists to select for CTC with the technology
allowing for assessment of up to four additional protein expressions on the surface of CTC's.
Additional samples at the proposed time points will be placed on ice and sent over to the
Wang Laboratory for the purpose of extracting RNA/microRNA and proteins from CTC's for
profiling and further analysis. Benefits are only to society, not the individual. Knowledge
obtained from applying the two technologies may help with better selection of therapy, early
detection of progression, possibly better diagnosis and development of targeted therapeutic
agents in the future.
be delivered to the Bruce Laboratory (Palo Alto Research Center) for immunolabeling and FAST
scanning. The FAST scanning will utilize CK+, CD45-and DAPI+ labeling as well as cell
morphology confirmed by collaborating pathologists to select for CTC with the technology
allowing for assessment of up to four additional protein expressions on the surface of CTC's.
Additional samples at the proposed time points will be placed on ice and sent over to the
Wang Laboratory for the purpose of extracting RNA/microRNA and proteins from CTC's for
profiling and further analysis. Benefits are only to society, not the individual. Knowledge
obtained from applying the two technologies may help with better selection of therapy, early
detection of progression, possibly better diagnosis and development of targeted therapeutic
agents in the future.
Inclusion Criteria:
- Patients must be > 18 years old.
- Patients are being treated for breast cancer at City of Hope (COH).
We found this trial at
1
site
Duarte, California 91010
Principal Investigator: Yuan Yuan, MD, PhD
Phone: 800-826-4673
Click here to add this to my saved trials
